Fetal Anomalies Scan at the Time of Nuchal Translucency Study

Fetal Anomalies Clinical Trial

Official title:

Fetal Anomalies Scan at the Time of Nuchal Translucency Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00943189
• Other study ID #: SHEBA-08-4934-LG-CTIL
• Status: Recruiting
• Phase: N/A
• First received: July 21, 2009
• Last updated: November 19, 2009
• Start date: June 2008

Study information

• Verified date: November 2009
• Source: Sheba Medical Center
• Contact: Liat Gindes, MD
• Email: gindesl[@]smile.net.il
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Observational

Clinical Trial Summary

Purpose: Fetal anomalies scan at the time of Nuchal Translucency (NT) study.

Description:

Prospective study of patients at 12-14 weeks gestation that are coming for NT examination is conducted. Meticulous ultrasound examination will be done to the fetuses using trans vaginal and transabdominal techniques. The patients will receive only the NT information. Only in cases of detection of severe fetal anomalies the patient will get the information of the examination and counseling according to the findings. All patients will be asked to provide information of the 15 weeks early comprehensive ultrasound examination. The NT examination will be compared to the 15 weeks ultrasound. All patients will be asked to give information after delivery of the baby's health condition.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• pregnant women at 12-14 weeks

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Congenital Abnormalities
• Fetal Anomalies

Locations

Country	Name	City	State
Israel	Sheba Medical Center	Ramat Gan

Sponsors (1)

Lead Sponsor	Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel,